POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients by C Katlama et al.
BioMed Central
Journal of the International AIDS 
Society
ssOpen AccePoster presentation
POWER 1 and 2: combined final 144-week efficacy and safety results 
for darunavir/ritonavir (DRV/r) 600/100 mg BID in 
treatment-experienced HIV patients
C Katlama*1, N Bellos2, B Grinsztejn3, A Lazzarin4, A Pozniak5, S De Meyer6, 
T Van De Casteele6 and S Spinosa-Guzman6
Address: 1Hôpital Pitié-Salpêtrière, Paris, France, 2Southwest Infectious Disease Associates, Dallas, USA, 3Instituto de Pesquisa Clinica Evandro 
Chagas-FIOCRUZ, Rio de Janeiro, Brazil, 4Clinic of Infectious Diseases, Milan, Italy, 5Chelsea and Westminster Hospital, London, UK and 6Tibotec 
BVBA, Mechelen, Belgium
* Corresponding author    
Background
POWER 1 and 2 (TMC114-C213 and C202) are ran-
domised, controlled, Phase IIb trials designed to evaluate
the long-term efficacy and safety of darunavir co-adminis-
tered with low-dose ritonavir (DRV/r) in comparison with
control protease inhibitor (CPIs) in treatment-experi-
enced HIV patients. This combined analysis evaluates the
final 144-week efficacy, safety and tolerability results for
DRV/r 600/100 mg BID.
Methods
Patients had documented HIV-1 infection, with ≥1 pri-
mary PI mutation and HIV-RNA >1,000 copies/mL at
baseline. The analysis included patients in POWER 1 and
2 randomised to receive DRV/r 600/100 mg BID or
CPI(s), plus an optimised background regimen (OBR;
NRTIs ± enfuvirtide). The primary efficacy end-point was
the proportion of patients with ≥1 log10 HIV-RNA reduc-
tion at week 144 from baseline (time-to-loss of virological
response [TLOVR] algorithm) in the intent-to-treat (ITT)
population.
Summary of results
There were 513 patients in the DRV/r group (of whom
131 received DRV/r 600/100 mg BID) and 124 patients in
the CPI group. Baseline data for the DRV/r 600/100 mg
BID group were: 89% male, 81% Caucasian, mean age 44
years, mean duration of infection 12 years, mean log10
HIV-RNA 4.6 copies/mL, median CD4 cell count 153
cells/mm3, 36% CDC category C, median primary PI
mutations 3. More than 90% of patients had previously
used ≥4 NRTIs, ≥1 NNRTI or ≥2 PIs. All patients had
reached week 144 or discontinued earlier (discontinua-
tions: DRV/r 600/100 mg BID n = 49 [37%]; CPI n = 108
[87%]). At week 144, 48 (37%) patients in the DRV/r 600/
100 mg BID group and 11 (9%) patients in the CPI group
achieved HIV-RNA <50 copies/mL (p < 0.001; ITT-
TLOVR). A ≥1 log10 HIV-RNA reduction was achieved by
67 (51%) patients in the DRV/r 600/100 mg BID group
and 12 (10%) patients in the CPI group (p < 0.001; ITT-
TLOVR). The median CD4 cell count increased from base-
line by 97 cells/mm3 in the DRV/r 600/100 mg BID group
and 4 cells/mm3 in the CPI group (p < 0.001; last observa-
tion carried forward analysis). The most common treat-
ment-emergent adverse events from week 24 onwards in
patients receiving DRV/r 600/100 mg BID over a median
exposure of 120 weeks were diarrhoea (16%), nasophar-
yngitis (14%), sinusitis (13%) and bronchitis (13%).
Most adverse events were grade 1 or 2.
Conclusion
Combined final efficacy and safety results for POWER 1
and 2 confirm that DRV/r 600/100 mg BID has long-term
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